Published in J Am Soc Nephrol on January 05, 2012
miR-150 promotes renal fibrosis in lupus nephritis by downregulating SOCS1. J Am Soc Nephrol (2013) 1.57
TGF-β/Smad signaling in renal fibrosis. Front Physiol (2015) 1.36
TGF-β: the master regulator of fibrosis. Nat Rev Nephrol (2016) 1.19
Transforming growth factor-β-induced cross talk between p53 and a microRNA in the pathogenesis of diabetic nephropathy. Diabetes (2013) 1.15
MicroRNAs: potential mediators and biomarkers of diabetic complications. Free Radic Biol Med (2013) 1.08
MicroRNAs and diabetic complications. J Cardiovasc Transl Res (2012) 1.04
PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs. PPAR Res (2012) 1.03
Epigenetic modifications in the pathogenesis of diabetic nephropathy. Semin Nephrol (2013) 1.02
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. PLoS One (2014) 1.01
Circulating and urinary microRNA profile in focal segmental glomerulosclerosis: a pilot study. Eur J Clin Invest (2015) 1.00
miR-21 contributes to xenon-conferred amelioration of renal ischemia-reperfusion injury in mice. Anesthesiology (2013) 0.99
MicroRNAs in renal fibrosis. Front Physiol (2015) 0.98
TGF-β induces acetylation of chromatin and of Ets-1 to alleviate repression of miR-192 in diabetic nephropathy. Sci Signal (2013) 0.97
Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice. Kidney Int (2013) 0.96
Metabolic memory and chronic diabetes complications: potential role for epigenetic mechanisms. Curr Diab Rep (2012) 0.96
Regulation of inflammatory phenotype in macrophages by a diabetes-induced long noncoding RNA. Diabetes (2014) 0.95
TGFβ-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion. PLoS One (2012) 0.94
MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets. Ann N Y Acad Sci (2015) 0.92
The role of microRNAs in diabetic nephropathy. J Diabetes Res (2014) 0.91
MicroRNA and nephropathy: emerging concepts. Int J Nephrol Renovasc Dis (2013) 0.90
In-Silico Algorithms for the Screening of Possible microRNA Binding Sites and Their Interactions. Curr Genomics (2013) 0.88
MicroRNAs as pharmacological targets in diabetes. Pharmacol Res (2013) 0.88
The regulation and function of microRNAs in kidney diseases. IUBMB Life (2013) 0.87
Arecoline-induced myofibroblast transdifferentiation from human buccal mucosal fibroblasts is mediated by ZEB1. J Cell Mol Med (2014) 0.87
Epigenetics of progression of chronic kidney disease: fact or fantasy? Semin Nephrol (2013) 0.86
Circulating TGF-β1-Regulated miRNAs and the Risk of Rapid Progression to ESRD in Type 1 Diabetes. Diabetes (2015) 0.86
Urine miRNAs: potential biomarkers for monitoring progression of early stages of diabetic nephropathy. Med Hypotheses (2013) 0.86
Serum microRNAs levels in primary focal segmental glomerulosclerosis. Pediatr Nephrol (2013) 0.85
MicroRNAs as novel therapeutic targets to treat kidney injury and fibrosis. Am J Physiol Renal Physiol (2016) 0.84
MicroRNAs and their applications in kidney diseases. Pediatr Nephrol (2014) 0.84
MicroRNAs are potential therapeutic targets in fibrosing kidney disease: lessons from animal models. Drug Discov Today Dis Models (2013) 0.84
Present and future in the treatment of diabetic kidney disease. J Diabetes Res (2015) 0.84
MicroRNA-21 inhibits platelet-derived growth factor-induced human aortic vascular smooth muscle cell proliferation and migration through targeting activator protein-1. Am J Transl Res (2014) 0.83
Mini-review: emerging roles of microRNAs in the pathophysiology of renal diseases. Am J Physiol Renal Physiol (2015) 0.83
MicroRNA regulation in renal pathophysiology. Int J Mol Sci (2013) 0.82
Anti-Inflammatory Role of MicroRNA-146a in the Pathogenesis of Diabetic Nephropathy. J Am Soc Nephrol (2015) 0.82
MicroRNAs as potential therapeutic targets in kidney disease. J Formos Med Assoc (2013) 0.82
Modulation of immune responses following solid organ transplantation by microRNA. Exp Mol Pathol (2012) 0.82
Age and sex differences in kidney microRNA expression during the life span of F344 rats. Biol Sex Differ (2015) 0.81
Role of regulatory micro RNAs in type 2 diabetes mellitus-related inflammation. Nucleic Acid Ther (2012) 0.81
Delivery of microRNA-146a with polyethylenimine nanoparticles inhibits renal fibrosis in vivo. Int J Nanomedicine (2015) 0.81
MicroRNAs: new insights into chronic childhood diseases. Biomed Res Int (2013) 0.81
Epigenetics in kidney development and renal disease. Transl Res (2014) 0.80
Influence of erythropoietin on microvesicles derived from mesenchymal stem cells protecting renal function of chronic kidney disease. Stem Cell Res Ther (2015) 0.79
Berberine ameliorates chronic kidney injury caused by atherosclerotic renovascular disease through the suppression of NFκB signaling pathway in rats. PLoS One (2013) 0.79
MiRNA inhibition in tissue engineering and regenerative medicine. Adv Drug Deliv Rev (2014) 0.79
MicroRNAs in Diabetic Nephropathy: From Biomarkers to Therapy. Curr Diab Rep (2016) 0.79
Molecular signaling cascade of miRNAs in causing Diabetes Nephropathy. Bioinformation (2013) 0.78
Human angiotensinogen +11525 C/A polymorphism modulates its gene expression through microRNA binding. Physiol Genomics (2013) 0.78
Early detection of diabetic kidney disease: Present limitations and future perspectives. World J Diabetes (2016) 0.78
Differential microRNA Profiles Predict Diabetic Nephropathy Progression in Taiwan. Int J Med Sci (2016) 0.77
Transforming growth factor-beta and the glomerular filtration barrier. Kidney Res Clin Pract (2013) 0.77
Characterization of miRNA-regulated networks, hubs of signaling, and biomarkers in obstruction-induced bladder dysfunction. JCI Insight (2017) 0.77
Skewed Epigenetics: An Alternative Therapeutic Option for Diabetes Complications. J Diabetes Res (2015) 0.77
RLIP76 protein knockdown attenuates obesity due to a high-fat diet. J Biol Chem (2013) 0.77
Redox Signaling in Diabetic Nephropathy: Hypertrophy versus Death Choices in Mesangial Cells and Podocytes. Mediators Inflamm (2015) 0.76
Genetics and Epigenetics of Diabetic Nephropathy. Kidney Dis (Basel) (2015) 0.76
Differential microRNA expression in the serum of patients with nephrotic syndrome and clinical correlation analysis. Int J Clin Exp Pathol (2015) 0.76
MicroRNA-196a/b Mitigate Renal Fibrosis by Targeting TGF-β Receptor 2. J Am Soc Nephrol (2016) 0.76
Identification of microRNAs and their target genes in Alport syndrome using deep sequencing of iPSCs samples. J Zhejiang Univ Sci B (2015) 0.76
Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease. J Diabetes Investig (2017) 0.75
Epigenetic Histone Modifications Involved in Profibrotic Gene Regulation by 12/15-Lipoxygenase and Its Oxidized Lipid Products in Diabetic Nephropathy. Antioxid Redox Signal (2015) 0.75
Epigenetics of Renal Development and Disease. Yale J Biol Med (2016) 0.75
The Expression of miR-192 and Its Significance in Diabetic Nephropathy Patients with Different Urine Albumin Creatinine Ratio. J Diabetes Res (2016) 0.75
MicroRNA-145 regulates platelet-derived growth factor-induced human aortic vascular smooth muscle cell proliferation and migration by targeting CD40. Am J Transl Res (2016) 0.75
PGC1α Activators Mitigate Diabetic Tubulopathy by Improving Mitochondrial Dynamics and Quality Control. J Diabetes Res (2017) 0.75
Crucial genes associated with diabetic nephropathy explored by microarray analysis. BMC Nephrol (2016) 0.75
The Effect of Regular Moderate Exercise on miRNA-192 Expression Changes in Kidney of Streptozotocin-Induced Diabetic Male Rats. Adv Pharm Bull (2015) 0.75
Inhibiting MicroRNA-503 and MicroRNA-181d with Losartan Ameliorates Diabetic Nephropathy in KKAy Mice. Med Sci Monit (2016) 0.75
Differential Expression of microRNAs in Urinary Extracellular Vesicles Obtained From Hypertensive Patients. Am J Kidney Dis (2016) 0.75
Epigenetic Regulations in Diabetic Nephropathy. J Diabetes Res (2017) 0.75
Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice. Mol Ther (2017) 0.75
MicroRNA-192 regulates hypertrophic scar fibrosis by targeting SIP1. J Mol Histol (2017) 0.75
Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 32.56
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol (2008) 24.27
A pancreatic islet-specific microRNA regulates insulin secretion. Nature (2004) 15.02
miRNAs, cancer, and stem cell division. Cell (2005) 12.15
LNA-mediated microRNA silencing in non-human primates. Nature (2008) 11.45
A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell (2009) 6.03
MicroRNA control of signal transduction. Nat Rev Mol Cell Biol (2010) 5.74
Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res (2007) 5.67
MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A (2007) 4.92
TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol (2009) 4.05
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell (2010) 3.52
Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A (1993) 3.16
Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res (2004) 3.11
MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J (2008) 2.75
Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J Am Soc Nephrol (2008) 2.74
Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J Am Soc Nephrol (2008) 2.69
miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J Am Soc Nephrol (2010) 2.51
MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res (2008) 2.51
Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury. J Am Soc Nephrol (2008) 2.51
Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol (2010) 2.45
A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells. Kidney Int (2011) 2.30
Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res (2005) 2.20
Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes (1995) 2.12
Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int (2008) 2.09
miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression. Diabetes (2010) 1.95
E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes (2010) 1.85
Targeted deletion of Dicer from proximal tubules protects against renal ischemia-reperfusion injury. J Am Soc Nephrol (2010) 1.82
The extracellular matrix in diabetic nephropathy. Am J Kidney Dis (1993) 1.81
MicroRNAs and their role in progressive kidney diseases. Clin J Am Soc Nephrol (2009) 1.77
Role of the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. J Am Soc Nephrol (2006) 1.71
MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J Biol Chem (2011) 1.68
Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes (1989) 1.64
Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci U S A (2000) 1.61
MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One (2011) 1.60
Intrarenal expression of miRNAs in patients with hypertensive nephrosclerosis. Am J Hypertens (2009) 1.59
Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. J Biol Chem (2010) 1.42
Intrarenal expression of microRNAs in patients with IgA nephropathy. Lab Invest (2009) 1.41
In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucleic Acids Res (2003) 1.38
New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol (2010) 1.29
Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes (2010) 1.29
The miRNA-192/194 cluster regulates the Period gene family and the circadian clock. FEBS J (2009) 1.27
miR-200b precursor can ameliorate renal tubulointerstitial fibrosis. PLoS One (2010) 1.23
Abnormalities in signaling pathways in diabetic nephropathy. Expert Rev Endocrinol Metab (2010) 1.19
Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes. Am J Physiol Renal Physiol (2008) 1.16
Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol Cancer Ther (2007) 1.04
Regulation of WNK1 expression by miR-192 and aldosterone. J Am Soc Nephrol (2010) 0.97
microRNA cascade in diabetic kidney disease: Big impact initiated by a small RNA. Cell Cycle (2009) 0.88
MiR-192 inhibits nucleotide excision repair by targeting ERCC3 and ERCC4 in HepG2.2.15 cells. Biochem Biophys Res Commun (2011) 0.85
MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A (2007) 4.92
TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol (2009) 4.05
Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci U S A (2008) 2.33
A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells. Kidney Int (2011) 2.30
Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaB-dependent inflammatory genes. Relevance to diabetes and inflammation. J Biol Chem (2008) 2.17
High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes (2003) 2.14
In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem (2004) 2.07
PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci U S A (2009) 2.07
IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res (2011) 1.87
The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol (2010) 1.83
Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes (2014) 1.81
MicroRNAs and their role in progressive kidney diseases. Clin J Am Soc Nephrol (2009) 1.77
Retracted Role of the lysine-specific demethylase 1 in the proinflammatory phenotype of vascular smooth muscle cells of diabetic mice. Circ Res (2008) 1.74
Role of the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. J Am Soc Nephrol (2006) 1.71
Diabetic conditions promote binding of monocytes to vascular smooth muscle cells and their subsequent differentiation. Am J Physiol Heart Circ Physiol (2009) 1.63
Growth factors induce monocyte binding to vascular smooth muscle cells: implications for monocyte retention in atherosclerosis. Am J Physiol Cell Physiol (2004) 1.62
Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J (2007) 1.62
Differential behavior of mesangial cells derived from 12/15-lipoxygenase knockout mice relative to control mice. Kidney Int (2003) 1.60
Mapping global histone methylation patterns in the coding regions of human genes. Mol Cell Biol (2005) 1.55
Genome-wide analysis of histone lysine methylation variations caused by diabetic conditions in human monocytes. J Biol Chem (2007) 1.54
Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells. J Biol Chem (2006) 1.52
12/15-Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo. J Biol Chem (2003) 1.50
Enhanced proatherogenic responses in macrophages and vascular smooth muscle cells derived from diabetic db/db mice. Diabetes (2006) 1.49
Elevated glucose and diabetes promote interleukin-12 cytokine gene expression in mouse macrophages. Endocrinology (2006) 1.47
Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes. Diabetes (2008) 1.46
Epigenetic histone methylation modulates fibrotic gene expression. J Am Soc Nephrol (2010) 1.44
Epigenetic mechanisms in diabetic vascular complications. Cardiovasc Res (2011) 1.43
Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. J Biol Chem (2010) 1.42
Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J Biol Chem (2003) 1.35
Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h1. Diabetes (2010) 1.32
PU.1 and C/EBP(alpha) synergistically program distinct response to NF-kappaB activation through establishing monocyte specific enhancers. Proc Natl Acad Sci U S A (2011) 1.30
Novel long noncoding RNAs are regulated by angiotensin II in vascular smooth muscle cells. Circ Res (2013) 1.30
Fast population coding. Neural Comput (2007) 1.26
Involvement of p300/CBP and epigenetic histone acetylation in TGF-β1-mediated gene transcription in mesangial cells. Am J Physiol Renal Physiol (2012) 1.26
Protein inhibitor of activated STAT Y (PIASy) and a splice variant lacking exon 6 enhance sumoylation but are not essential for embryogenesis and adult life. Mol Cell Biol (2004) 1.24
Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia (2014) 1.22
Cell type and culture condition-dependent alternative splicing in human breast cancer cells revealed by splicing-sensitive microarrays. Cancer Res (2006) 1.21
Epigenetics: deciphering its role in diabetes and its chronic complications. Clin Exp Pharmacol Physiol (2011) 1.17
Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney: reversal by angiotensin II type 1 receptor blockade. Circulation (2005) 1.17
Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes. Am J Physiol Renal Physiol (2008) 1.16
Transforming growth factor-β-induced cross talk between p53 and a microRNA in the pathogenesis of diabetic nephropathy. Diabetes (2013) 1.15
Effects of silencing leukocyte-type 12/15-lipoxygenase using short interfering RNAs. J Lipid Res (2004) 1.15
Distinct roles of heterogeneous nuclear ribonuclear protein K and microRNA-16 in cyclooxygenase-2 RNA stability induced by S100b, a ligand of the receptor for advanced glycation end products. J Biol Chem (2008) 1.14
Coactivator-associated arginine methyltransferase-1 enhances nuclear factor-kappaB-mediated gene transcription through methylation of histone H3 at arginine 17. Mol Endocrinol (2006) 1.14
Angiotensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: a novel cross-talk in the pathogenesis of atherosclerosis. Circ Res (2005) 1.12
Small RNA sequencing reveals microRNAs that modulate angiotensin II effects in vascular smooth muscle cells. J Biol Chem (2012) 1.09
Glucose regulates interleukin-8 production in aortic endothelial cells through activation of the p38 mitogen-activated protein kinase pathway in diabetes. J Biol Chem (2004) 1.09
Epigenetics in diabetic kidney disease. J Am Soc Nephrol (2011) 1.09
MicroRNAs: potential mediators and biomarkers of diabetic complications. Free Radic Biol Med (2013) 1.08
Knockout of the transcription factor NRF2 disrupts spermatogenesis in an age-dependent manner. Free Radic Biol Med (2010) 1.08
Cooperation of SRC-1 and p300 with NF-kappaB and CREB in angiotensin II-induced IL-6 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2007) 1.07
Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells. Am J Physiol Renal Physiol (2002) 1.07
Novel interactions between TGF-{beta}1 actions and the 12/15-lipoxygenase pathway in mesangial cells. J Am Soc Nephrol (2004) 1.06
Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocytes. Diabetes (2004) 1.05
Proinflammatory effects of advanced lipoxidation end products in monocytes. Diabetes (2007) 1.05
MicroRNAs and diabetic complications. J Cardiovasc Transl Res (2012) 1.04
Interaction of monocytes with vascular smooth muscle cells regulates monocyte survival and differentiation through distinct pathways. Arterioscler Thromb Vasc Biol (2004) 1.03
Epigenetic modifications in the pathogenesis of diabetic nephropathy. Semin Nephrol (2013) 1.02
Profiles of epigenetic histone post-translational modifications at type 1 diabetes susceptible genes. J Biol Chem (2012) 1.02
Enhancers: multi-dimensional signal integrators. Transcription (2012) 1.02
Pro-inflammatory role of microrna-200 in vascular smooth muscle cells from diabetic mice. Arterioscler Thromb Vasc Biol (2012) 1.02